Author/Authors :
Naderi، Malihe نويسنده Department of Microbiology, Qom branch, Islamic Azad University, Qom 37185-364, Iran. Naderi, Malihe , Gholipour، Naghmeh نويسنده National Institute of Genetic Engineering and Biotechnology, Department of Molecular Genetic, Tehran, Iran , , Zolfaghari، Mohammad Reza نويسنده , , Moradi Binabaj، Maryam نويسنده Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran. Moradi Binabaj, Maryam , Yegane Moghadam، Ahmad نويسنده Department of Otolaryngology, Kashan University of Medical Sciences, Kashan, Iran. Yegane Moghadam, Ahmad , Motalleb، Gholamreza نويسنده ,
Abstract :
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-? and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine.
